N/A N=60 Wellness Coaching for Caregivers of Thoracic Transplant Candidates
Stress, Psychological · Caregiver Burden
Primary: Acceptability — 30; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=178 Tele-Self CBTI Trial
Insomnia Disorder
Primary: Insomnia Severity — 16.1; 16.1; 10.4; 14.1 ISI score — p=<0.01
N/A N=54 A Comparison of Serum and Urine N-telopeptide Marker
Osteoporosis · Fractures, Bone
Primary: Correlation Between NTX Measures With Each Other — 0.52 r-value — p=<0.001
Phase 2 N=67 A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
Crohn Disease · Ulcerative Colitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 18; 19; 2; 2 Participants
N/A N=45 Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators
Human Papilloma Virus
Primary: Acceptability of At-home Self-collection for HPV Testing Among Under-screened Women in Southwest Virginia. — 45 Participants
N/A N=11 Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
Pulmonary Fibrosis · Anxiety
Primary: Part 1 - Subject Feedback on Functionality and Experience of the dCBT-PF at Week 4 — 8; 2; 2; 1 Participants
N/A N=31 An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
Sun Damaged Skin
Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…
Phase 4 N=25 Erenumab for Idiosyncratic Facial Pain
Facial Pain · Rhinosinusitis
Primary: Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure — -6.0; -5.8 days per month — p=0.96
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 2 N=61 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Lichen Sclerosus
Primary: Percentage of Participants With ITCH4 at Week 12 — 35.7; 40.0 percentage of participants — p=0.737
N/A N=20 The Conformal Prague Study
Non-valvular Atrial Fibrillation
Primary: Freedom From Major Adverse Events — 19 Participants
Phase 2 N=1,068 Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia
Ventilator-acquired Pneumonia
Primary: Quality of Life - 36-item Short-Form General Health Survey — 40.5; 40.0; 48.9; 45.9 score on a scale — p=0.78
N/A N=8 MetaNeb® Chest X-ray Study
Atelectasis
Primary: Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System. — 1.63; 1.75; 1.25; 1.13 scores on a scale
Phase 2 N=35 A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Impact of MN-166 on [11C]-PBR28 Uptake in the Motor Cortices and Brain Stem Measured by Positron Emission Tomography (PET) Imaging at 12 - 24 Weeks — 0.0015 SUV ratio
N/A N=130 Orthosensor vs Conventional Total Knee Arthroplasty
Osteoarthritis, Knee
Primary: Average Score on the 12-Item Short Form Survey (SF-12) - Physical Component — 46; 43; 45; 46 score on a scale